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Abstract
Introduction: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) support on pharmacokinetics of
oseltamivir and oseltamivir carboxylate (OC) in children.
Methodology: Steady state 0–12 hour pharmacokinetic sampling was performed in new influenza A (H1N1) infected
children treated with oseltamivir while on ECMO support. Cmax, Cmin and AUC0–12 h were calculated. The age-specific
oseltamivir dosage was doubled to counter expected decreased plasma drug concentrations due to increased volume of
distribution on ECMO support.
Principal Findings: Three patients were enrolled aged 15, 6 and 14 years in this pharmacokinetic case series. For two
children the OC plasma concentrations were higher than those found in children and adults not on ECMO. These increased
plasma concentrations related to the increased oseltamivir dosage and decreased kidney function. In one patient
suboptimal plasma concentrations coincided with a decreased gastric motility.
Conclusion: Oseltamivir pharmacokinetics do not appear to be significantly influenced by ECMO support. Caution is
required in case of nasogastric administration and decreased gastric motility. Due to the limited number of (paediatric)
patients available further multicenter studies are warranted.
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Introduction
Currently the first influenza pandemic of this century is almost
at its end. The new variant influenza A (H1N1) virus appears to be
relatively mild compared to its pandemic predecessors. [1] Still, a
life threatening disease pattern not characteristic for seasonal
influenza has been identified in often young patients infected with
new variant influenza A (H1N1). The clinical picture of this severe
illness is one of Acute Respiratory Distress Syndrome (ARDS),
sometimes associated with septicaemia-like symptoms. While
relatively rare, these cases impose a burden on intensive care
units. [2,3,4]
The optimal treatment for children and adolescents with
influenza associated ARDS has not yet been established. Based
on recent data, mostly obtained in adults, the use of extra
corporeal membrane oxygenation (ECMO) support in combina-
tion with the use of neuraminidase inhibitors appears to be a
feasible option. [3] ECMO support is associated with altered
pharmacokinetics for several drugs. This is due to the increment of
the total circulation volume and adherence to plastic tubing and
membranes. [5] Suboptimal plasma concentrations of neuramin-
idase inhibitors may be associated with reduced antiviral
effectiveness of the drug and the development of viral drug
resistance. [6] The aim of this study is to evaluate the effect of
ECMO support on plasma concentrations of oseltamivir and
oseltamivir carboxylate (OC) in children.
Methods
This is a prospective analysis of pharmacokinetic data from new
influenza A (H1N1) infected children (0–18 years) treated with
oseltamivir that required ECMO support (Medtronic Sh. 70 USP
class VI 3/863/32 superTygonH, Medtronic, Minneapolis, USA).
As routine protocol the age-specific oseltamivir dosage was
doubled to counter expected decreased plasma drug concentra-
tions due to ECMO support. This resulted in the following
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90 mg/day q12 h, 23–40 kg: 120 mg/day q12 h and .40 kg:
150 mg/day q12 h. Medication was administered though naso-
gastric or duodenal tube. According to our hospital based ECMO
protocol continuous venovenous hemofiltration (CVVH) (Multi-
flow 100 Hospal, Lyon, France) was performed during ECMO as
a standard treatment.
Twenty-four hours after initiation of ECMO support blood
samples were obtained from the ECMO system in BD
Hemocard
TM EDTA/NaF tubes. Sampling was performed at 0-
1-2-4-6-12 hours after oral administration of oseltamivir suspen-
sion 15 mg/ml (patient 1) and 12 mg/ml (patient 2 and 3). After
sampling and centrifugation, the supernatant serum was stored
at 280uC and shipped in batch. Plasma concentrations for
oseltamivir and OC were determined by PRA, Bio-analytical
Laboratory Assen, the Netherlands by a commercial validated
HPLC assy.
Medical data was collected using a Patient Data Management
System. Written informed consent was obtained from parent or
care takers prior to enrolment. The study was approved by the
institutional medical ethics committee (Medisch Ethische Toets-
ings Commissie Erasmus MC (METC). METC#-2006-355 and
ABR#NL14729.078.06.)
Results
Three patients were enrolled (1 girl, 2 boys) aged 6, 14 and 15
years in this pharmacokinetic case series. A total of 17 samples (6,
6 and 5 samples each) were available for analysis. None of the
patients had a medical history that could influence the oseltamivir
pharmacokinetics. All patients required ECMO due to ARDS.
Patient 1 and 2 received enteral feeding and tamiflu suspension via
a duodenal tube. Patient 3 had severe gastro-enteric bleeding and
decreased gastric motility with gastric residue as a result of
septicaemia accompanied with diffuse intravascular coagulopathy.
Medication in this patient was administered via a gastric tube.
Patient 1 and 3 had decreased renal function expressed by
increased creatinine concentrations at the time of sampling (see
table 1). ECMO flow rates and hemofiltration rates were not
adjusted during sampling.
The results of the pharmacokinetics concentrations of
oseltamivir and OC are presented in table 1 and figures 1 and
2. In patient 3 suboptimal plasma concentrations were observed
for both the parent drug and OC. These coincided with a
decreased gastric mobility and nasogastric medication admin-
istration. For none of the patients adverse medication reactions
were reported
Discussion
In this pharmacokinetic case study high plasma concentrations
for OC were achieved in two out of three patients. Both patients
had plasma concentrations that were almost two fold higher
compared to historical controls in children aged 3–5 years and 13–
18 receiving 2 mg/kg oseltamivir. [7,8] The elevated plasma
concentrations found in our study reflect in part the higher dosing
used in our patients. In addition, the (mild) renal impairment seen
in patient 1 may also have led to an increase in plasma OC
concentrations. In a study by He et al. this has also been shown in
adults with mild to severe renal failure. [9]
The plasma concentrations found in this case series show a
marked variance. This was previously also seen in non critically ill
children. [7,8] Age related changes in the clearance of OC may be
an additional explanation. [7] Patient 3 clearly had suboptimal
serum concentrations of both oseltamivir and OC. In this patient
the absorption of oseltamivir was severely impaired due to gastric
bleeding and decreased gastric motility. In critically ill adults two
studies report that oseltamivir can be safely used and is adequately
absorbed following nasogastric administration. [10,11] Our
finding warrants caution in patients with severe GI problems,
not only in ECMO patients but in all critically ill patients with GI
problems. We propose that in these patients, conversion to inhaled
or when available intravenous medication (i.e. zanamivir) is
indicated.
Table 1. Baseline characteristics of patients.
Patient 1 2 3
Age (years) 15 6 14
Dosage (Q12 h) 150 120 150
Dosage (Q12 h/kg) 3 4 2,7#
Sex Female Male Male
Creatinine (mmol/l) 88 32 100
Formulation and route of administration Suspension, Duodenal tube Suspension, Duodenal tube Suspension, Gastric tube
Oseltamivir
Cmax (ng/ml) 92.4 41.4 3.4
Cmin (ng/ml) 1.9 0 0
AUC0–12 h (ngxh/ml) 232.9 87.4 25
Oseltamivir carboxylase
Cmax (ng/ml) 1300 548 224
Cmin (ng/ml) 736 236 77,2
AUC0–12 h (mgxh/ml) 10642 3211 978,1
# Weight estimated, due to critical illness and later death impossible to weigh.
doi:10.1371/journal.pone.0010938.t001
Oseltamivir Dosing on ECMO
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can not be made based on our findings. Still this is the first study to
show that adequate plasma concentration of oseltamivir and
oseltamivir carboxylate can be achieved in critically ill patients on
ECMO. The two fold dose increment that we did in this study
does not seem to be necessary to achieve adequate plasma
concentrations. However, further research is needed to confirm
these findings. A multicenter approach would be preferable, to
allow for sufficient inclusions in an acceptable time period.
In conclusion oseltamivir pharmacokinetics do not seem to be
significantly influenced by ECMO support. Caution is required in
case of nasogastric administration and decreased gastric mobility.
In these patients another route of antiviral medication should be
considered. We propose to conduct further study on this subject in
a lager group of patients
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Figure 1. Oseltamivir concentrations in plasma. Plasma concen-
trations (mg/l) are depicted for each individual patient in time (h).
Individualpatients aremarkedwith a colour code andmaker: patient 1:0,
black; patient 2 n, blue and patient 3: ,,red.
doi:10.1371/journal.pone.0010938.g001
Figure2. OC concentrations in plasma. Plasma concentrations (mg/l)
aredepicted for each individualpatient in time(h). Individual patients are
marked with a colour code and maker: patient 1: 0, black; patient 2 n,
blue and patient 3: ,,red.
doi:10.1371/journal.pone.0010938.g002
Oseltamivir Dosing on ECMO
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e10938